88 related articles for article (PubMed ID: 25052606)
1. [Effect of CCL3 on osteoblast in myeloma bone disease].
Zhao S; Fu R; Liu H; Wang Y; Li L; Liu C; Zhang T; Ding S; Gao S; Ruan E; Qu W; Wang H; Wang X; Wu Y; Song J; Liu H; Guan J; Shao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):623-7. PubMed ID: 25052606
[TBL] [Abstract][Full Text] [Related]
2. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
[TBL] [Abstract][Full Text] [Related]
3. [Culture and regulation of osteoblasts in multiple myeloma patients].
Gao S; Fu R; Liu H; Liu H; Song J; Wang H; Wang G; Xing L; Shao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):202-6. PubMed ID: 24666484
[TBL] [Abstract][Full Text] [Related]
4. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.
Liu L; Yu Z; Cheng H; Mao X; Sui W; Deng S; Wei X; Lv J; Du C; Xu J; Huang W; Xia S; An G; Zhou W; Ma X; Cheng T; Qiu L; Hao M
Sci Rep; 2020 Nov; 10(1):20508. PubMed ID: 33239656
[TBL] [Abstract][Full Text] [Related]
6. CCR1 as a target for multiple myeloma.
Vallet S; Anderson KC
Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.
Vande Broek I; Leleu X; Schots R; Facon T; Vanderkerken K; Van Camp B; Van Riet I
Haematologica; 2006 Feb; 91(2):200-6. PubMed ID: 16461304
[TBL] [Abstract][Full Text] [Related]
8. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts.
Lean JM; Murphy C; Fuller K; Chambers TJ
J Cell Biochem; 2002; 87(4):386-93. PubMed ID: 12397598
[TBL] [Abstract][Full Text] [Related]
9. Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor.
Karadag A; Scutt AM; Croucher PI
J Bone Miner Res; 2000 Oct; 15(10):1935-43. PubMed ID: 11028445
[TBL] [Abstract][Full Text] [Related]
10. Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease.
Fu R; Liu H; Zhao S; Wang Y; Li L; Gao S; Ruan E; Wang G; Wang H; Song J; Shao Z
Cancer Cell Int; 2014; 14(1):132. PubMed ID: 25520585
[TBL] [Abstract][Full Text] [Related]
11. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms for formation of myeloma bone disease].
Yata K; Abe M; Matsumoto T
Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
14. Dual role of CCL3/CCR1 in oral squamous cell carcinoma: implications in tumor metastasis and local host defense.
Silva TA; Ribeiro FL; Oliveira-Neto HH; Watanabe S; Alencar Rde C; Fukada SY; Cunha FQ; Leles CR; Mendonça EF; Batista AC
Oncol Rep; 2007 Nov; 18(5):1107-13. PubMed ID: 17914560
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone, BMP-2, and 1,25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts.
Jørgensen NR; Henriksen Z; Sørensen OH; Civitelli R
Steroids; 2004 Apr; 69(4):219-26. PubMed ID: 15183687
[TBL] [Abstract][Full Text] [Related]
16. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
17. Human hemarthrosis-derived progenitor cells can differentiate into osteoblast-like cells in vitro.
Niikura T; Miwa M; Sakai Y; Lee SY; Kuroda R; Fujishiro T; Kubo S; Doita M; Kurosaka M
Biochem Biophys Res Commun; 2005 Nov; 336(4):1234-40. PubMed ID: 16171789
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O
Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110
[TBL] [Abstract][Full Text] [Related]
19. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2.
Rickard DJ; Sullivan TA; Shenker BJ; Leboy PS; Kazhdan I
Dev Biol; 1994 Jan; 161(1):218-28. PubMed ID: 8293874
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of fetal osteoblasts and formation of mineralized bone nodules by 45S5 Bioglass conditioned medium in the absence of osteogenic supplements.
Tsigkou O; Jones JR; Polak JM; Stevens MM
Biomaterials; 2009 Jul; 30(21):3542-50. PubMed ID: 19339047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
